87,500 Pfizer Inc. $PFE Shares Sold by Arnhold LLC

Key Points

• Arnhold LLC reduced its Pfizer position by 87,500 shares, or 8.6%, leaving it with 931,297 shares valued at approximately $26.6 million. Institutional investors collectively own 68.36% of Pfizer.
• Pfizer shares opened at $29.80 and are near their 52-week high, while the company’s latest results exceeded expectations with $0.77 in EPS and $15.03 billion in revenue. Analysts maintain a consensus “Hold” rating with an average price target of $28.72.
• The company announced a quarterly dividend of $0.43 per share, equivalent to a 5.8% annualized yield. Pfizer also received expanded FDA approval for TALZENNA plus XTANDI in certain prostate cancer patients, potentially broadening the treatment’s market opportunity.

Arnhold LLC lessened its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 8.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 931,297 shares of the biopharmaceutical company's stock after selling 87,500 shares during the period. Pfizer accounts for 1.9% of Arnhold LLC's holdings, making the stock its 14th biggest holding. Arnhold LLC's holdings in Pfizer were worth $26,561,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Bank of America Corp DE acquired a new stake in Pfizer in the second quarter valued at $1,049,602,000. BlackRock Inc. grew its position in shares of Pfizer by 6.3% in the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company's stock valued at $12,754,464,000 after buying an additional 31,412,883 shares during the last quarter. Nykredit A S acquired a new stake in shares of Pfizer in the second quarter valued at about $205,774,000. Assenagon Asset Management S.A. increased its stake in shares of Pfizer by 96.0% in the second quarter. Assenagon Asset Management S.A. now owns 11,902,374 shares of the biopharmaceutical company's stock valued at $286,609,000 after buying an additional 5,829,204 shares during the period. Finally, State Street Corp raised its position in shares of Pfizer by 1.8% during the second quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company's stock worth $7,394,749,000 after acquiring an additional 5,501,032 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA expanded approval of TALZENNA (talazoparib) in combination with XTANDI (enzalutamide) for men with metastatic hormone-sensitive prostate cancer whose tumors have homologous recombination repair (HRR) gene mutations, including BRCA and non-BRCA mutations. Moving the treatment into an earlier stage of metastatic disease could enlarge the addressable patient population and support future sales growth. Pfizer's TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting
• Positive Sentiment: Pfizer also reported Phase 2 results across serotypes for its 25-valent pneumococcal conjugate vaccine candidate, 25vPnC. The update adds visibility to the company’s vaccine pipeline, though the available report does not provide enough detail to assess the results’ commercial significance. Pfizer announces results across serotypes in Phase 2 study of 25vPnC
• Neutral Sentiment: Pfizer’s shares have gained about 29.7% over the past year and are near their 52-week high, prompting discussion over whether the valuation is ahead of the company’s earnings growth. Investors may require further pipeline or operating improvements to justify additional gains. Pfizer Stock Looks Above Fair Value As 30% Run Continues
• Neutral Sentiment: Pfizer was relatively resilient while Moderna and BioNTech declined amid disappointment over cancer-vaccine trial data. The comparison may offer some support for PFE, but it does not directly change Pfizer’s fundamentals. Moderna Tumbles as Cancer Vaccine Selloff Deepens
• Negative Sentiment: Broader healthcare stocks traded lower, creating sector-level pressure on Pfizer. Separately, an experimental Pfizer lung-cancer drug showed a survival benefit in some patients despite a failed trial, leaving its development outlook uncertain rather than providing a clear catalyst. Healthcare Stocks Softer Monday

Pfizer Stock Performance

Shares of Pfizer stock opened at $29.80 on Tuesday. The business has a 50-day simple moving average of $28.30 and a 200 day simple moving average of $26.67. Pfizer Inc. has a one year low of $23.62 and a one year high of $30.44. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The firm has a market capitalization of $169.82 billion, a price-to-earnings ratio of 9.85, a PEG ratio of 2.04 and a beta of 0.32.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The business had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the prior year, the company earned $0.78 earnings per share. The company's quarterly revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts anticipate that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 5.8%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer's dividend payout ratio is presently 226.32%.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on PFE. Bank of America cut their price objective on Pfizer from $27.00 to $26.00 and set a "neutral" rating on the stock in a research note on Friday, July 10th. HSBC increased their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a "hold" rating in a research report on Thursday, September 10th. Cantor Fitzgerald raised their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a report on Thursday, October 8th. Wall Street Zen downgraded shares of Pfizer from a "buy" rating to a "hold" rating in a research report on Saturday, October 10th. Finally, BMO Capital Markets reduced their price objective on shares of Pfizer from $34.00 to $30.00 and set an "outperform" rating on the stock in a research note on Monday, July 13th. Five equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $28.72.

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company's portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.